Molecular Hydrogen Mediates Neurorestorative Effects After Stroke in Diabetic Rats: the TLR4/NF-κB Inflammatory Pathway
Yang WC, Li TT, Wan Q, Zhang X, Sun LY, Zhang YR, Lai PC, Li WZ. · Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology. 2023;18(1-2):90-99.
What kind of evidence is this?
Preclinical
Controlled animal and cell study
Metabolic and lipid health
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
rats, cells, rat, tissue used to study metabolic and lipid health.
Preclinical study; group or assay counts reported in the full text include n=30, n=18, n=12, n=6.
60 min
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 60 min, 20 min, 3.0 L/min, 42%, 21%, 37%.
Inhaled molecular H₂ at 42%; oxygen co-delivery is reported.
H₂-related quantities reported in the intervention passages: 60 min, 20 min, 3.0 L/min, 42%, 21%, 37%. Values are not combined across different experimental arms.
1260 mL/min H₂, calculated from 42% H₂ and 3000 mL/min total flow reported in the full text.
21% O₂; 630 mL/min O₂ calculated from the reported total flow.
Control or comparison condition reported in the full article; see the linked methods for arm-specific details.
Outcomes and reported result
survival or mortality, clinical symptoms or functional scores, inflammation and cytokines, apoptosis or cell injury, histology or tissue damage, metabolic laboratory measures
Article-reported result excerpt (24 words maximum): “Compared with rats in group M (52.9%), molecular hydrogen treatment induced significant survival benefits, group H (80%) and group HN (77.8%) survived to the…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Preclinical evidence only; findings do not establish a treatment effect in people. No funding statement was identified in the machine-readable full article; absence is not inferred. The full article contains a conflict, commercial-support or supplied-product declaration; consult the source wording.
Applies to the reported animal, cell or tissue model, not directly to patients.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 35895245 · DOI: 10.1007/s11481-022-10051-w
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10